Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lanoracopan - Wuhan Createrna Science and Technology

Next Previous
Drug Profile

Lanoracopan - Wuhan Createrna Science and Technology

Alternative Names: Factor B-IN-5 - Wuhan Createrna Science and Technology; Lanoracopan hydrochloride - Wuhan Createrna Science and Technology; Lanoracopan hydrochloride tablets - Wuhan Createrna Science and Technology; MY-008; MY-008211A; Yishining

Latest Information Update: 20 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Wuhan Createrna Science and Technology
  • Class Amines; Benzoic acids; Cyclopropanes; Ethers; Indoles; Piperidines; Small molecules
  • Mechanism of Action Complement factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Paroxysmal nocturnal haemoglobinuria
  • Phase II IgA nephropathy

Most Recent Events

  • 08 Jul 2026 Wuhan Langlai Science and Technology plans to file marketing authorization application for IgA nephropathy
  • 08 Jul 2026 Efficacy data from a phase II trial in IgA nephropathy released by Wuhan Langlai Science and Technology
  • 08 Jul 2026 Lanoracopan - Wuhan Createrna Science and Technology receives Breakthrough Therapy status for IgA nephropathy in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top